AU674026B2 - Translocation signal facilitated nuclear delivery of macromolecules - Google Patents

Translocation signal facilitated nuclear delivery of macromolecules

Info

Publication number
AU674026B2
AU674026B2 AU50885/93A AU5088593A AU674026B2 AU 674026 B2 AU674026 B2 AU 674026B2 AU 50885/93 A AU50885/93 A AU 50885/93A AU 5088593 A AU5088593 A AU 5088593A AU 674026 B2 AU674026 B2 AU 674026B2
Authority
AU
Australia
Prior art keywords
domain
dna
polypeptide
gene
domains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU50885/93A
Other languages
English (en)
Other versions
AU5088593A (en
Inventor
Thomas R. Barnett
Rathindra C Das
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Bayer AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Bayer Corp filed Critical Bayer AG
Publication of AU5088593A publication Critical patent/AU5088593A/en
Assigned to BAYER CORPORATION reassignment BAYER CORPORATION Amend patent request/document other than specification (104) Assignors: MILES INC.
Application granted granted Critical
Publication of AU674026B2 publication Critical patent/AU674026B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Formation Of Insulating Films (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU50885/93A 1992-08-25 1993-08-24 Translocation signal facilitated nuclear delivery of macromolecules Ceased AU674026B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93507492A 1992-08-25 1992-08-25
PCT/US1993/007945 WO1994004696A1 (fr) 1992-08-25 1993-08-24 Apport nucleaire de macromolecules facilite par un signal de translocation
US935074 1997-09-25

Publications (2)

Publication Number Publication Date
AU5088593A AU5088593A (en) 1994-03-15
AU674026B2 true AU674026B2 (en) 1996-12-05

Family

ID=25466554

Family Applications (1)

Application Number Title Priority Date Filing Date
AU50885/93A Ceased AU674026B2 (en) 1992-08-25 1993-08-24 Translocation signal facilitated nuclear delivery of macromolecules

Country Status (10)

Country Link
EP (1) EP0658210A1 (fr)
JP (1) JPH08504565A (fr)
KR (1) KR950703650A (fr)
AU (1) AU674026B2 (fr)
CA (1) CA2143308A1 (fr)
FI (1) FI950866A7 (fr)
IL (1) IL106760A (fr)
NZ (1) NZ255870A (fr)
WO (1) WO1994004696A1 (fr)
ZA (1) ZA936189B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674977A (en) * 1993-02-05 1997-10-07 The Ontario Cancer Institute Branched synthetic peptide conjugate
AU6568594A (en) * 1993-04-14 1994-11-08 Boehringer Mannheim Gmbh Nucleic acid tranfer peptides and their use for injecting nucleic acids into eucaryotic cells
EP0745134A1 (fr) 1994-02-22 1996-12-04 Danafarber Cancer Institute Systeme de liberation d'acide nucleique, son procede de synthese et ses utilisations
US6037329A (en) 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
EP0753069A1 (fr) * 1994-04-15 1997-01-15 Targeted Genetics Corporation Proteine de fusion d'apport de gene
US6468981B1 (en) * 1994-07-29 2002-10-22 Emory University Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors
JPH09511916A (ja) * 1994-11-01 1997-12-02 ベルス，ビンフリート 核酸伝達系
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
CA2251691A1 (fr) * 1996-03-26 1997-10-02 Razvan T. Radulescu Peptide presentant des proprietes antiproliferatives
US5877282A (en) * 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
US5962415A (en) * 1996-09-20 1999-10-05 Bristol-Myers Squibb Co. Compositions comprising a peptide inhibitor of nuclear protein translocation and an immunosuppressant and methods of use thereof
DE19649645A1 (de) * 1996-11-29 1998-06-04 Hoechst Ag Mehrfach funktionelles Ligandensystem zur zielzellspezifischen Übertragung von Nukleotidsequenzen
US6086900A (en) * 1997-03-26 2000-07-11 Board Of Regents, The University Of Texas Systems Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
GB9713122D0 (en) * 1997-06-20 1997-08-27 Chiron Spa Novel method of DNA transfer into cells
WO1999007723A1 (fr) * 1997-08-07 1999-02-18 University Of Maryland, Baltimore Vehicule de fixation d'apport d'acide nucleique
NZ512244A (en) 1998-11-12 2003-12-19 Invitrogen Corp Polycationic transfection reagents for introducing anions into a cell
AU2983100A (en) * 1999-02-06 2000-08-25 Aurx, Inc. Drug delivery vehicle
DE19910419A1 (de) * 1999-03-10 2000-09-21 Aventis Pharma Gmbh Zielzellspezifische, multivalente Proteine (MVP)
FR2793414B1 (fr) * 1999-05-10 2003-05-23 Centre Nat Rech Scient Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules
US6387684B1 (en) * 1999-09-13 2002-05-14 Academia Sinica Topoisomerase 1-mediated DNA delivery
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
EP1222289B1 (fr) * 1999-10-20 2008-04-16 The Johns Hopkins University School Of Medicine Compositions chimeriques immunogenes et acides nucleiques codant pour de telles compositions
DE10019157A1 (de) * 2000-04-18 2001-11-15 Stefan Duebel Verfahren zum Einbringen von Liganden in lebende Zellen
JP5087201B2 (ja) 2000-08-03 2012-12-05 ジョンズ・ホプキンス・ユニバーシティ 抗原に小胞体シャペロンポリペプチドを連結した分子ワクチン
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
WO2002083166A1 (fr) * 2001-04-10 2002-10-24 Santen Pharmaceutical Co., Ltd. Complexes de polymeres d'interferons et leur utilisation medicinale
EP1947116B1 (fr) * 2003-02-10 2017-06-21 2-BBB Medicines B.V. Acides nucléiques exprimés par action différentielle dans la barrière hématoencéphalique sous des conditions inflammatoires
US9701725B2 (en) 2003-05-05 2017-07-11 The Johns Hopkins University Anti-cancer DNA vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
WO2005054438A2 (fr) 2003-12-01 2005-06-16 Invitrogen Corporation Molecule d'acide nucleique contenant des sites de recombinaison et leurs procedes d'utilisation
CA2594040A1 (fr) 2005-01-06 2006-07-13 The Johns Hopkins University Interference arn bloquant l'expression de l'immunite potentialisee de proteines pro-apoptotiques induite par adn et des vaccins de cellules dendritiques transfectes
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
EP2334693A4 (fr) * 2008-07-18 2011-09-21 Chee Keong Choo Procédés de culture à long terme de cellules eucaryotes et utilisations de ceux-ci
EP3169310A1 (fr) 2014-07-15 2017-05-24 Life Technologies Corporation Compositions comprenant des agrégats lipidiques et procédés d'administration efficace de molécules dans des cellules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05505102A (ja) * 1989-12-21 1993-08-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 真核細胞の中に分子を配達する方法
EP0556197A4 (en) * 1990-09-25 1994-05-18 Univ Connecticut Prolonging expression of polynucleotides introduced into a cell
DE4139001A1 (de) * 1991-11-27 1993-06-03 Boehringer Mannheim Gmbh Verfahren zur einschleusung von nukleinsaeuren in zellen
WO1993017102A1 (fr) * 1992-02-19 1993-09-02 The Trustees Of The University Of Pennsylvania MODULATION DE FONCTIONS CELLULAIRES AVEC DES PROTEINES HnRNP
CA2131620A1 (fr) * 1992-03-20 1993-09-30 Louis C. Smith Systeme de transport de l'adn et mode d'emploi

Also Published As

Publication number Publication date
IL106760A (en) 1999-12-31
FI950866L (fi) 1995-04-24
CA2143308A1 (fr) 1994-03-03
AU5088593A (en) 1994-03-15
JPH08504565A (ja) 1996-05-21
WO1994004696A1 (fr) 1994-03-03
KR950703650A (ko) 1995-09-20
EP0658210A1 (fr) 1995-06-21
FI950866A0 (fi) 1995-02-24
NZ255870A (en) 1996-09-25
IL106760A0 (en) 1993-12-08
ZA936189B (en) 1995-01-10
FI950866A7 (fi) 1995-04-24

Similar Documents

Publication Publication Date Title
AU674026B2 (en) Translocation signal facilitated nuclear delivery of macromolecules
US6498233B1 (en) Nucleic acid transfer system
Fominaya et al. Target cell-specific DNA transfer mediated by a chimeric multidomain protein: novel non-viral gene delivery system
Wagstaff et al. Nucleocytoplasmic transport of DNA: enhancing non-viral gene transfer
Schwartz et al. Synthetic DNA-compacting peptides derived from human sequence enhance cationic lipid-mediated gene transfer in vitro and in vivo
US7999073B2 (en) Modular transfection systems
US6720310B1 (en) Transfer method for specific cellular localization of nucleic acids
JP2001503385A (ja) ポリヌクレオチド送達のための組成物および方法
CA2241923C (fr) Systeme de transfert de genes par l'intermediaire de recepteurs pour therapie genique ciblee de tumeurs
NZ521563A (en) Peptide conjugates for drug delivery
CA2331384A1 (fr) Phage de transfert d'acide nucleique
Min et al. Gene delivery using a derivative of the protein transduction domain peptide, K-Antp
Sloots et al. Recombinant derivatives of the human high‐mobility group protein HMGB2 mediate efficient nonviral gene delivery
Hellgren et al. Factors controlling the efficiency of Tat-mediated plasmid DNA transfer
AU2020310380A1 (en) Complex for intracellular delivery of molecules
US20090155853A1 (en) Non-viral gene delivery complex
Kim et al. Cell-penetrating DNA-binding protein as a safe and efficient naked DNA delivery carrier in vitro and in vivo
US20230391836A1 (en) Amino acid sequence that can destroy cells, and related nucleotide sequence and related uses thereof
WO2025245094A2 (fr) Séquences peptidiques pour l'administration améliorée de protéines dans un noyau
Ning A bioresponsive peptide as a single component gene vector
Rolland et al. Pharmaceutical gene medicines for non-viral gene therapy
Parker Development of peptide-targeted gene delivery systems
MXPA99003470A (en) Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired